AGS-003: Additional Phase II data

Additional data from an ongoing, open-label Phase II trial in 21 newly diagnosed metastatic RCC patients with an unfavorable prognosis showed that AGS-003 every 3 weeks plus sunitinib led to a median PFS of 11.9 months compared to a historical PFS of 8 months for sunitinib alone. Additionally, 11 of 15 evaluable patients treated with AGS-003 plus sunitinib had increases in anti-tumor memory T cells, including CD28+ T cells. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...